Percutaneous Exposures of volunteers to polychromatic light (480-3400 nm) trigger systemic mechanism of the human myeloma cells growth delay without any effect on bortezomib cytotoxicity in vitro

Abstract

Polychromatic light is actively used in medicine. However, its oncological safety and effect against cytotoxic therapy remains poorly studied. Multiple myeloma (MM) develops in the bone marrow and therefore malignant plasma cells are inaccessible to direct exposure to light. The aim of our work was to study the influence of polychromatic visible and infra-red light (pVIS + pIR) on growth and sensitivity of the myeloma cells to the cytotoxic effect of drug bortezomib (BTZ) through systemic mechanism. We explored the effect of volunteers blood sera after their 4-daily irradiations with pVIS + pIR light (480-3400 nm) on growth and viability of the human myeloma RPMI 8226 cells in the presence of BTZ at its application in 2 modes: short-term (1 h, 300 nM) and long-term ( 96 h, 5 nM). Viability and proliferative activity of cells was evaluated by MTT assay. It was found that photomodified blood sera delayed growth of myeloma RPMI 8226 cells (by 25 % in 48 h and 23 % in 96 h) but had no effect on spontaneous and mitogen-induced proliferation of autologous peripheral blood T- and B-lymphocytes. We also revealed that pVIS + pIR did not change RPMI 8226 cells sensitivity to BTZ. The results suggest the systemic mechanism of polychromatic light and argue in favor of its oncological safety during/after BTZ therapy of MM patients without effect on the drug cytotoxicity.